35 years) - 2018 Edition: Forecast to 20" />
Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds


Press Release

Global Cervical Cancer Diagnostics (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies) Market 2018-2022 - ResearchAndMarkets.com

Research and Markets
Posted on: 21 Mar 18

The "Global Cervical Cancer Diagnostics Market: By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (<35 years, 35 years, >35 years) - 2018 Edition: Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.

The global market is projected to display a modest growth represented by a CAGR of 5.69% during 2017 - 2022, chiefly driven by growing healthcare awareness and increasing expenditure in healthcare sector.

On account of growing urbanization, there has been rising awareness regarding the benefits of periodic screening for cervical cancer. Additionally, growing female population in concurrence with medical infrastructural developments in emerging economies has been instrumental in boosting the demand for cervical cancer diagnostics. Amongst the type of cervical cancer diagnostic tests, cytology based screening solutions such as Pap and HPV, held the majority market share of more than 50%, by value, in the year 2016.

Moreover, HPV tests are gaining market share on account of advantageous characteristics such as reliable and accurate result, reasonable cost, longer time gap between tests, and so on. Among the regions, North America and Europe together represents the largest regional market for global cervical cancer diagnostics market, chiefly driven by high per capita expenditure on healthcare, as well as availability of advanced medical infrastructure.

The report titled, Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (< 35 years, 35 years, >35 years) - 2018 Edition: Forecast to 2022, has covered and analysed the potential of cervical cancer diagnostics market across the globe and provides statistics and information on market size, shares and growth factors.

The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global cervical cancer diagnostics market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Cervical Cancer Outlook

5. Global Cervical Cancer Diagnostics Market: Growth and Forecast

6. Global Cervical Cancer Diagnostics Market: An Analysis

7. Global Cervical Cancer Diagnostics Market: Regional Analysis

8. Global Cervical Cancer Diagnostics Market Dynamics

9. Global Cervical Cancer Diagnostics Market Trends

10. Porter Five Force Analysis

11. SWOT Analysis

12. Supply Chain Analysis

13. Pricing Analysis

14. Competitive Landscape

15. Policy and Regulatory Landscape

16. Company Profiles

  • Abott Laboratories
  • Arbor Vita Corporation
  • Becton
  • Dickinson and Company
  • Guided Therapeutics
  • Hologic
  • Qiagen
  • Quest Diagnostics
  • Roche

For more information about this report visit https://www.researchandmarkets.com/research/rgkhc5/global_cervical?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180321005454/en/

Business Wire

Last updated on: 21/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.